



Curriculum Vitae

Personal information **Juha Vakkilainen**

Work experience

1. Employer: Finnish Medicines Agency
 - Start date: 092005
 - End date:
 - Position: Senior Medical Officer
 - Activities:
 - Country: Finland

Education and training

1. Subject: University of Helsinki
 - Start date:
 - End date:
 - Qualification: M.D., Ph.D.
 - Organisation:
 - Country: Finland

Additional information

Publications

Manolis E, Brogren J, Cole S, Hay JL, Nordmark A, Karlsson KE, Lentz F, Benda N, Wangorsch G, Pons G, Zhao W, Gigante V, Serone F, Standing JF, Dokoumetzidis A, Vakkilainen J, van den Heuvel M, Mangas Sanjuan V, Taminiau J, Kerwash E, Khan D, Musuamba FT, Skottheim Rusten I; EMA Modelling and Simulation Working Group. Commentary on the MID3 Good Practices Paper. *CPT Pharmacometrics Syst Pharmacol*. 2017 Jul;6(7):416_417. Tornio A, Vakkilainen J, Neuvonen M, Backman JT, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid. *Pharmacogenet Genomics*. 2015 Aug;25(8):382_7. PMID: 26020121 Xiang X, Vakkilainen J, Backman JT, Neuvonen PJ, Niemi M. No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid. *Eur J Clin Pharmacol*. 2011 Nov;67(11):1159_67. PubMed PMID: 21655991. Kahri J, Fruchart_Najib J, Matikainen N, Fruchart JC, Vakkilainen J, Taskinen MR. The increase of apolipoprotein A_V during postprandial lipemia parallels the response of triglyceride_rich lipoproteins in type 2 diabetes: no relationship between apoA_V and postheparin plasma lipolytic activity. *Diabetes Care*. 2007 Aug;30(8):2083_5. PubMed PMID: 17485571. Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher C, Hamsten A, Taskinen MR; DAIS Group. Relationships between low_density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). *Circulation*. 2003 Apr 8;107(13):1733_7. PubMed PMID: 12665498. Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. *Diabetes Metab Res Rev*. 2002 Nov-Dec;18(6):484_90. PubMed PMID: 12469362. Vakkilainen J, Pajukanta P, Cantor RM, Nuotio IO, Lahdenperä S, Ylitalo K, Pihlajamäki J, Kovanen PT, Laakso M, Viikari JS, Peltonen L, Taskinen MR. Genetic influences contributing to LDL particle size in familial combined hyperlipidaemia. *Eur J Hum Genet*. 2002 Sep;10(9):547_52. PubMed PMID: 12173032. Liu ML, Ylitalo K, Vakkilainen J, Nuotio I, Valkonen M, Lahdenperä S, Viikari J, Taskinen MR. Susceptibility of LDL to oxidation in vitro and antioxidant capacity in familial combined hyperlipidemia: comparison of patients with different lipid phenotypes. *Ann Med*. 2002;34(1):48_54. PubMed PMID: 12014434. Vakkilainen J, Jauhainen M, Ylitalo K, Nuotio IO, Viikari JS, Ehnholm C, Taskinen MR. LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein_modifying enzymes, and lipid transfer proteins. *J Lipid Res*. 2002 Apr;43(4):598_603. PubMed PMID: 11907142. Vakkilainen J, Steiner G, Ansquer JC, Perttunen_Nio H, Taskinen MR. Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes. *Diabetes Care*. 2002 Mar;25(3):627_8. PubMed PMID: 11874962. Ylitalo K, Pajukanta P, Meri S, Cantor RM, Mero_Matikainen N, Vakkilainen J, Nuotio I, Taskinen MR. Serum C3 but not plasma acylation_stimulating protein is elevated in Finnish patients with familial combined hyperlipidemia. *Arterioscler Thromb Vasc Biol*. 2001 May;21(5):838_43. PubMed PMID: 11348883. Ylitalo K, Large V, Pajukanta P, Reynisdottir S, Porkka KV, Vakkilainen J, Nuotio I, Taskinen MR, Arner P. Reduced hormone_sensitive lipase activity is not a major metabolic defect in Finnish FCHL families. *Atherosclerosis*. 2000 Dec;153(2):373_81. PubMed PMID: 11164426. Vakkilainen J, Mäkimattila S, Seppälä_Lindroos A, Vehkavaara S, Lahdenperä S, Groop PH, Taskinen MR, Yki_Järvinen H. Endothelial dysfunction in men with small LDL particles. *Circulation*. 2000 Aug 15;102(7):716_21. PubMed PMID: 10942737. Vehkavaara S, Mäkimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki_Järvinen H. Insulin therapy improves endothelial function in type 2 diabetes. *Arterioscler Thromb Vasc Biol*. 2000 Feb;20(2):545_50. PubMed PMID: 10669655. Mäkimattila S, Liu ML, Vakkilainen J, Schlenzka A, Lahdenperä S, Syväne M, Mäntysaari M, Summanen P, Bergholm R, Taskinen MR, Yki_Järvinen H. Impaired endothelium_dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants. *Diabetes Care*. 1999 Jun;22(6):973_81. PubMed PMID: 10372251. Vakkilainen J, Porkka KV, Nuotio I, Pajukanta P, Suurinkeroinen L, Ylitalo K, Viikari JS, Ehnholm C, Taskinen MR. Glucose intolerance in familial combined hyperlipidaemia. EUFAM study group. *Eur J Clin Invest*. 1998 Jan;28(1):24_32. PubMed PMID: 9502184. Ylitalo K, Porkka KV, Meri S, Nuotio I, Suurinkeroinen L, Vakkilainen J, Pajukanta P, Viikari JS, Peltonen L, Ehnholm C, Taskinen MR. Serum complement and familial combined hyperlipidemia. *Atherosclerosis*. 1997 Mar 21;129(2):271_7. PubMed PMID: 9105570.

Projects

Memberships

Other Relevant Information